Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M ...

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experienceSeres is implementing a focused ...
CURE

FDA OKs Breakthrough Status to Rybrevant Faspro in Head and Neck Cancer

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
Scientific Research Publishing

Protective Effects of Vitamin D in Necrotizing Enterocolitis of Preterm Infants: From Basic Research to Clinical Translation ()

Protective Effects of Vitamin D in Necrotizing Enterocolitis of Preterm Infants: From Basic Research to Clinical Translation. Journal of Biosciences and Medicines, 14, 42-56. doi: ...

Feline Chronic Gingivostomatitis: Clinical Data on Stem Cell Efficacy from Gallant

The presentation of chronic feline gingivostomatitis is often dramatic. Clinical signs include severe refractory gingivostomatitis, halitosis, ptyalism, and unkempt hair coats due to a lack of ...

Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Takeda Pharmaceutical Company Limited ( TAK) TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM EST ...

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
Canadian Medical Association Journal

Irreversible blindness induced by vitamin A deficiency in a child with avoidant/restrictive food intake disorder secondary to Noonan syndrome

Key points A 4-year-old boy presented to our urgent ophthalmology clinic for photophobia and persistent eye rubbing. He had been born at 39 weeks via Cesarean delivery, without complications. Prenatal ...
PharmiWeb

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...